Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SIX1
REST API REST API
Homo sapiens
SIX1 is differentially expressed in 246 experiments: 158 organism parts: pituitary gland, prostate, ... (156 more);, 175 disease states: normal, colon carcinoma, ... (173 more);, 70 cell types 375 cell lines 30 compound treatments and 61 other conditions.
Synonyms DFNA23
Orthologs six1a (Danio rerio)   Six1 (Mus musculus)   Six1 (Rattus norvegicus)   six1b (Danio rerio)   so (Drosophila melanogaster)   six1 (Xenopus laevis)   SIX1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term pattern specification process, DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, sequence-specific DNA binding, positive regulation of transcription from RNA polymerase II promoter, regulation of neuron differentiation, nucleus, transcription factor complex, chromatin binding, skeletal muscle tissue development, positive regulation of transcription, DNA-dependent, nucleolus, negative regulation of neuron apoptosis, outflow tract morphogenesis, pharyngeal system development, kidney development, branching involved in ureteric bud morphogenesis, inner ear development, ureter smooth muscle cell differentiation, embryonic skeletal system morphogenesis, anatomical structure development, positive regulation of branching involved in ureteric bud morphogenesis, inner ear morphogenesis, regulation of branch elongation involved in ureteric bud branching, embryonic cranial skeleton morphogenesis, thymus development, generation of neurons, thyroid gland development, myoblast migration, ureteric bud development, epithelial cell differentiation, otic vesicle development, sequence-specific DNA binding transcription factor activity, protein localization to nucleus, positive regulation of mesenchymal cell proliferation involved in ureter development, positive regulation of ureteric bud formation, mesonephric tubule formation, metanephric mesenchyme development, transcription regulatory region DNA binding, organ induction, aorta morphogenesis, positive regulation of secondary heart field cardioblast proliferation
InterPro Term Homeobox
UniProt Accession Q15475
Gene-Disease Assocation DEAFNESS, AUTOSOMAL DOMINANT 23; DFNA23, BRANCHIOOTIC SYNDROME 3; BOS3
Search EB-eye ENSG00000126778
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (38 experiments)

Factor Value U/D Experiments
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
AGS
2
E-GEOD-15460, E-MTAB-37
MCF-7
2
E-GEOD-20081, E-GEOD-3529
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
SNU16
2
E-MTAB-37, E-GEOD-15460
369 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (40 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
LCC
1
E-GEOD-19188
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
64 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-16363, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-16363, E-GEOD-21912
cervical carcinoma
2
E-MTAB-37, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1007
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
169 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5824, E-TABM-868, E-MEXP-1958, E-MEXP-2590, ... (20 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-TABM-868, E-GEOD-7400, ... (7 experiments)
1mM GDC-0941
1
1
E-GEOD-20719
DMSO
1
E-MEXP-1561
unknown
1
E-GEOD-7307
CNOT7+CNOT8
1
1
E-MEXP-2218
Cxcl12
1
E-GEOD-7307
24 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
adrenal gland; kidney
1
E-GEOD-5851
bone
1
E-GEOD-5851
liver
1
E-GEOD-5851


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-149, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1432, E-MEXP-2069, E-GEOD-1926, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.378 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM